Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

10/25/24 6:06:25 AM ET

$QTTB

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $QTTB alert in real time by email

SC 13G/A 1 d34526dsc13ga.htm SC 13G/A SC 13G/A

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2 )*

Q32 Bio Inc.

(Name of Issuer)

Common stock, par value $0.0001 per share

(Title of Class of Securities)

746964105

(CUSIP Number)

September 30, 2024

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐

Rule 13d-1(b)

☑

Rule 13d-1(c)

☐

Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 746964105		Page 2 of 9


1	NAMES OF REPORTING PERSONS Temasek Holdings (Private) Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Singapore
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 313,943
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 313,943
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 313,943
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.6%⁽¹⁾
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC

⁽¹⁾	Based on 12,059,786 shares of the Issuer’s common stock outstanding as of August 1, 2024, as set forth in the Issuer’s (as defined herein) quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the “Commission”) on August 8, 2024.


CUSIP No. 746964105		Page 3 of 9


1	NAMES OF REPORTING PERSONS Fullerton Management Pte Ltd
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Singapore
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 313,943
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 313,943
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 313,943
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.6%⁽¹⁾
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC

⁽¹⁾	Based on 12,059,786 shares of the Issuer’s common stock outstanding as of August 1, 2024, as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Commission on August 8, 2024.


CUSIP No. 746964105		Page 4 of 9


1	NAMES OF REPORTING PERSONS Temasek Life Sciences Private Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Singapore
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 313,943
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 313,943
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 313,943
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.6%⁽¹⁾
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC

⁽¹⁾	Based on 12,059,786 shares of the Issuer’s common stock outstanding as of August 1, 2024, as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Commission on August 8, 2024.


CUSIP No. 746964105		Page 5 of 9


1	NAMES OF REPORTING PERSONS V-Sciences Investments Pte Ltd
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Singapore
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 169,761
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 169,761
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 169,761
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.4%⁽¹⁾
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO

⁽¹⁾	Based on 12,059,786 shares of the Issuer’s common stock outstanding as of August 1, 2024, as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Commission on August 8, 2024.


CUSIP No. 746964105		Page 6 of 9

Item 1(a).

Name of Issuer:

Q32 Bio Inc. (the “Issuer”)

Item 1(b).

Address of Issuer’s Principal Executive Offices:

830 Winter Street, Waltham, MA 02451

Item 2(a).

Name of Person Filing:

This Schedule 13G is being jointly filed by the following reporting persons (each a “Reporting Person” and collectively, the “Reporting Persons”):

(i)

Temasek Holdings (Private) Limited (“Temasek”);

(ii)

Fullerton Management Pte Ltd (“FMPL”);

(iii)

Temasek Life Sciences Private Limited (“TLS”); and

(iv)

V-Sciences Investments Pte Ltd; (“V-Sciences”).

Item 2(b).

Address of Principal Business Office or, if none, Residence:

The address of the principal business office of each Reporting Person is 60B Orchard Road, #06-18, The Atrium@Orchard, Singapore 238891.

Item 2(c).

Citizenship:

Each

of the Reporting Persons: Republic of Singapore

Item 2(d).

Title of Class of Securities:

Common

stock, par value $0.0001 per share

Item 2(e).

CUSIP Number:

746964105

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.

Ownership.

(a)

Amount beneficially owned:

As of September 30, 2024, V-Sciences directly owned 169,761 shares of the Issuer’s Common Stock. V-Sciences is a wholly-owned subsidiary of TLS, which in turn is a wholly-owned subsidiary of FMPL, which in turn is a wholly-owned subsidiary of Temasek. Each of TLS, FMPL and Temasek, through the ownership described herein, may be deemed to beneficially own the shares directly owned by V-Sciences.

As of September 30, 2024, another wholly-owned subsidiary of TLS directly owned 144,182 shares of the Issuer’s Common Stock. TLS in turn is a wholly-owned subsidiary of FMPL, which in turn is a wholly-owned subsidiary of Temasek. Each of TLS, FMPL and Temasek, through the ownership described herein, may be deemed to beneficially own the shares directly owned by such wholly-owned subsidiary of TLS.

(b)

Percent of class:

As of September 30, 2024:

Temasek, FMPL, TLS: 2.6%

V-Sciences: 1.4%

The percentages above are based on 12,059,786 shares of the Issuer’s common stock outstanding as of August 1, 2024, as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Commission on August 8, 2024.

(c)

Number of shares as to which the person has:

With respect to the shared power to vote, or to direct the vote, and to dispose, or to direct the disposition of, the shares of the Issuer’s common stock, please see Item 4(a) above regarding qualifications as to beneficial ownership.


CUSIP No. 746964105		Page 7 of 9

(i)

Sole power to vote or to direct the vote:

(ii)

Shared power to vote or to direct the vote:

Temasek, FMPL and TLS: 313,943

V-Sciences: 169,761

(iii)

Sole power to dispose or to direct the disposition of:

(iv)

Shared power to dispose or to direct the disposition of:

Temasek, FMPL and TLS: 313,943

V-Sciences: 169,761

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒ .

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not Applicable.

Item 8.

Identification and Classification of Members of the Group.

Not Applicable.

Item 9.

Notice of Dissolution of Group.

Not Applicable.

Item 10.

Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


CUSIP No. 746964105		Page 8 of 9

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Dated: October 25, 2024	TEMASEK HOLDINGS (PRIVATE) LIMITED

	By:	/s/ Jason Norman Lee
		Name	:	Jason Norman Lee
		Title	:	Authorized Signatory

Dated: October 25, 2024	FULLERTON MANAGEMENT PTE LTD

	By:	/s/ Gregory Tan
		Name	:	Gregory Tan
		Title	:	Director

Dated: October 25, 2024	TEMASEK LIFE SCIENCES PRIVATE LIMITED

	By:	/s/ Lim Siew Lee Sherlyn
		Name	:	Lim Siew Lee Sherlyn
		Title	:	Director

Dated: October 25, 2024	V-SCIENCES INVESTMENTS PTE LTD

	By:	/s/ Khoo Ken Hui
		Name	:	Khoo Ken Hui
		Title	:	Director


CUSIP No. 746964105		Page 9 of 9

LIST OF EXHIBITS


Exhibit No.		Description

99.1		Joint Filing Agreement, dated as of April 11, 2018, by and among, Temasek, FMPL, TLS and V-Sciences and the other party named therein (incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons on April 11, 2018).

Get the next $QTTB alert in real time by email

Recent Analyst Ratings for

$QTTB

Date	Price Target	Rating	Analyst
2/11/2025	$22.00 → $3.00	Outperform → Market Perform	BMO Capital Markets
2/11/2025	$20.00 → $4.00	Overweight → Neutral	Piper Sandler
12/11/2024		Buy → Neutral	Guggenheim
12/11/2024	$95.00 → $16.00	Overweight → Equal Weight	Wells Fargo
12/11/2024	$90.00 → $22.00	Strong Buy → Outperform	Raymond James
12/11/2024	$68.00 → $9.00	Outperform → Market Perform	Leerink Partners
12/6/2024	$64.00	Outperform	BMO Capital Markets
10/24/2024	$90.00	Strong Buy	Raymond James

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

10/25/24 6:06:25 AM ET

$QTTB

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $QTTB alert in real time by email

SC 13G/A 1 d34526dsc13ga.htm SC 13G/A SC 13G/A

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2 )*

Q32 Bio Inc.

(Name of Issuer)

Common stock, par value $0.0001 per share

(Title of Class of Securities)

746964105

(CUSIP Number)

September 30, 2024

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐

Rule 13d-1(b)

☑

Rule 13d-1(c)

☐

Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.


CUSIP No. 746964105		Page 2 of 9


1	NAMES OF REPORTING PERSONS Temasek Holdings (Private) Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Singapore
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 313,943
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 313,943
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 313,943
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.6%⁽¹⁾
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC

⁽¹⁾	Based on 12,059,786 shares of the Issuer’s common stock outstanding as of August 1, 2024, as set forth in the Issuer’s (as defined herein) quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the “Commission”) on August 8, 2024.


CUSIP No. 746964105		Page 3 of 9


1	NAMES OF REPORTING PERSONS Fullerton Management Pte Ltd
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Singapore
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 313,943
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 313,943
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 313,943
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.6%⁽¹⁾
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC

⁽¹⁾	Based on 12,059,786 shares of the Issuer’s common stock outstanding as of August 1, 2024, as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Commission on August 8, 2024.


CUSIP No. 746964105		Page 4 of 9


1	NAMES OF REPORTING PERSONS Temasek Life Sciences Private Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Singapore
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 313,943
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 313,943
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 313,943
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.6%⁽¹⁾
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC

⁽¹⁾	Based on 12,059,786 shares of the Issuer’s common stock outstanding as of August 1, 2024, as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Commission on August 8, 2024.


CUSIP No. 746964105		Page 5 of 9


1	NAMES OF REPORTING PERSONS V-Sciences Investments Pte Ltd
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Singapore
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 169,761
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 169,761
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 169,761
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.4%⁽¹⁾
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO

⁽¹⁾	Based on 12,059,786 shares of the Issuer’s common stock outstanding as of August 1, 2024, as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Commission on August 8, 2024.


CUSIP No. 746964105		Page 6 of 9

Item 1(a).

Name of Issuer:

Q32 Bio Inc. (the “Issuer”)

Item 1(b).

Address of Issuer’s Principal Executive Offices:

830 Winter Street, Waltham, MA 02451

Item 2(a).

Name of Person Filing:

This Schedule 13G is being jointly filed by the following reporting persons (each a “Reporting Person” and collectively, the “Reporting Persons”):

(i)

Temasek Holdings (Private) Limited (“Temasek”);

(ii)

Fullerton Management Pte Ltd (“FMPL”);

(iii)

Temasek Life Sciences Private Limited (“TLS”); and

(iv)

V-Sciences Investments Pte Ltd; (“V-Sciences”).

Item 2(b).

Address of Principal Business Office or, if none, Residence:

The address of the principal business office of each Reporting Person is 60B Orchard Road, #06-18, The Atrium@Orchard, Singapore 238891.

Item 2(c).

Citizenship:

Each

of the Reporting Persons: Republic of Singapore

Item 2(d).

Title of Class of Securities:

Common

stock, par value $0.0001 per share

Item 2(e).

CUSIP Number:

746964105

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.

Ownership.

(a)

Amount beneficially owned:

(b)

Percent of class:

As of September 30, 2024:

Temasek, FMPL, TLS: 2.6%

V-Sciences: 1.4%

(c)

Number of shares as to which the person has:


CUSIP No. 746964105		Page 7 of 9

(i)

Sole power to vote or to direct the vote:

(ii)

Shared power to vote or to direct the vote:

Temasek, FMPL and TLS: 313,943

V-Sciences: 169,761

(iii)

Sole power to dispose or to direct the disposition of:

(iv)

Shared power to dispose or to direct the disposition of:

Temasek, FMPL and TLS: 313,943

V-Sciences: 169,761

Item 5.

Ownership of Five Percent or Less of a Class.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not Applicable.

Item 8.

Identification and Classification of Members of the Group.

Not Applicable.

Item 9.

Notice of Dissolution of Group.

Not Applicable.

Item 10.

Certification.


CUSIP No. 746964105		Page 8 of 9

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Dated: October 25, 2024	TEMASEK HOLDINGS (PRIVATE) LIMITED

	By:	/s/ Jason Norman Lee
		Name	:	Jason Norman Lee
		Title	:	Authorized Signatory

Dated: October 25, 2024	FULLERTON MANAGEMENT PTE LTD

	By:	/s/ Gregory Tan
		Name	:	Gregory Tan
		Title	:	Director

Dated: October 25, 2024	TEMASEK LIFE SCIENCES PRIVATE LIMITED

	By:	/s/ Lim Siew Lee Sherlyn
		Name	:	Lim Siew Lee Sherlyn
		Title	:	Director

Dated: October 25, 2024	V-SCIENCES INVESTMENTS PTE LTD

	By:	/s/ Khoo Ken Hui
		Name	:	Khoo Ken Hui
		Title	:	Director


CUSIP No. 746964105		Page 9 of 9

LIST OF EXHIBITS


Exhibit No.		Description

99.1		Joint Filing Agreement, dated as of April 11, 2018, by and among, Temasek, FMPL, TLS and V-Sciences and the other party named therein (incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons on April 11, 2018).

Get the next $QTTB alert in real time by email

Recent Analyst Ratings for

$QTTB

Date	Price Target	Rating	Analyst
2/11/2025	$22.00 → $3.00	Outperform → Market Perform	BMO Capital Markets
2/11/2025	$20.00 → $4.00	Overweight → Neutral	Piper Sandler
12/11/2024		Buy → Neutral	Guggenheim
12/11/2024	$95.00 → $16.00	Overweight → Equal Weight	Wells Fargo
12/11/2024	$90.00 → $22.00	Strong Buy → Outperform	Raymond James
12/11/2024	$68.00 → $9.00	Outperform → Market Perform	Leerink Partners
12/6/2024	$64.00	Outperform	BMO Capital Markets
10/24/2024	$90.00	Strong Buy	Raymond James

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$QTTB

Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$QTTB

$QTTB
Press Releases

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

$QTTB
Analyst Ratings

Q32 Bio downgraded by BMO Capital Markets with a new price target

Q32 Bio downgraded by Piper Sandler with a new price target

Q32 Bio downgraded by Guggenheim

$QTTB
Insider Trading

CEO Morrison Jodie Pope sold $18,900 worth of shares (10,494 units at $1.80), decreasing direct ownership by 8% to 121,506 units (SEC Form 4)

Chief Scientific Officer Violette Shelia M. sold $5,385 worth of shares (2,990 units at $1.80), decreasing direct ownership by 5% to 58,384 units (SEC Form 4)

CFO and President Kalowski Lee sold $7,636 worth of shares (4,240 units at $1.80), decreasing direct ownership by 8% to 49,010 units (SEC Form 4)

$QTTB
SEC Filings

SEC Form 8-K filed by Q32 Bio Inc.

SEC Form 10-Q filed by Q32 Bio Inc.

Q32 Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$QTTB
Financials

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

$QTTB
Large Ownership Changes